Caribou Biosciences (CRBU) Stock Price, News & Analysis

-0.13 (-3.27%)
(As of 05:22 PM ET)
Today's Range
50-Day Range
52-Week Range
1.08 million shs
Average Volume
1.63 million shs
Market Capitalization
$347.73 million
P/E Ratio
Dividend Yield
Price Target

Caribou Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
482.9% Upside
$22.50 Price Target
Short Interest
12.85% of Float Sold Short
Dividend Strength
News Sentiment
0.00mentions of Caribou Biosciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.76) to ($2.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.95 out of 5 stars

Medical Sector

789th out of 909 stocks

Biological Products, Except Diagnostic Industry

138th out of 156 stocks

CRBU stock logo

About Caribou Biosciences Stock (NASDAQ:CRBU)

Caribou Biosciences, Inc. is a cutting-edge biopharmaceutical company headquartered in Berkeley, California. Founded in 2011 by Dr. Rachel E. Haurwitz and other prominent scientists, the company is a leader in the field of genome-editing therapies. Caribou utilizes CRISPR-Cas technology to develop precision cell therapies for patients suffering from hematologic malignancies and solid tumors. The company's vision is to revolutionize the treatment landscape for devastating diseases by providing innovative and personalized therapies.

Caribou Biosciences' journey began as a spinoff from research conducted at the University of California, Berkeley, where Dr. Haurwitz and her colleagues worked on harnessing the CRISPR-Cas system for advanced gene-editing applications. Leveraging their expertise, the team established Caribou to explore the potential of genome editing in developing transformative therapeutics.

The company is committed to pushing the boundaries of science and medicine, focusing on creating precision cell therapies that target specific genetic mutations in patients' cells. By modifying these cells, Caribou aims to enhance antitumor activity and provide tailored treatments to address the unique genetic characteristics of each patient's disease.

Caribou Biosciences operates in the biological products industry, specializing in genome-editing therapies. The company's dedication to research and innovation has positioned it as a key player in the field, with significant potential to impact the future of medical treatments.

The company's mission statement revolves around the core belief in the power of genome-editing technology to unlock new possibilities for disease treatment and patient care. Caribou is committed to advancing its pipeline of precision cell therapies and translating cutting-edge science into transformative solutions for patients worldwide.

The leadership team at Caribou Biosciences comprises accomplished professionals with extensive expertise in the biopharmaceutical and scientific domains. Dr. Rachel E. Haurwitz, who co-founded the company and serves as the Chief Executive Officer, President, and Director. With a Ph.D. in Molecular and Cell Biology from UC Berkeley, Dr. Haurwitz was pivotal in developing CRISPR-based gene-editing technologies. Assisting Dr. Haurwitz is Ms. Ruhi A. Khan, the Chief Business Officer responsible for driving strategic partnerships and business development initiatives. Ms. Khan brings a wealth of experience in the biopharmaceutical industry and has been instrumental in shaping Caribou's collaborations. Dr. Syed Ali-aamir Rizvi serves as the Chief Medical Officer, contributing his expertise in clinical development and medical affairs. With a strong background in hematology and oncology, Dr. Rizvi is critical in guiding the clinical progress of Caribou's precision cell therapies. The management team's collective experience, dedication to innovation, and scientific prowess have propelled Caribou Biosciences to the forefront of the genome-editing industry.

Caribou Biosciences has demonstrated steady revenue growth over the past few years. However, the company is operating at a loss, with a net negative income of close to $100 million. The negative net profit margins result from substantial operating expenses associated with advancing the pipeline of precision cell therapies. Caribou Biosciences' innovative approach to precision cell therapies and its pioneering work in genome editing have garnered investor interest and positive sentiment, contributing to the stock's potential upside.

The stock performance of Caribou Biosciences is subject to various factors, including market conditions, investor sentiment, and news related to the company's progress. Investors closely monitor the company's milestones, clinical trial results, and partnership agreements, which can significantly impact the stock price.

Caribou Biosciences operates in the highly competitive field of biopharmaceuticals, focusing on genome-editing therapies. The broader industry has witnessed significant advancements in CRISPR technology, with various companies vying to develop precision cell therapies. Caribou's competitive advantage lies in its patented Cas12a chRDNA technology, which enables superior precision in genome editing and the development of armored cell therapies.

The company's pipeline of precision cell therapies presents promising growth opportunities. With its CAR-T and CAR-NK platforms targeting hematologic malignancies and solid tumors, Caribou aims to cater to patients with critical medical needs. The company's dedication to scientific excellence and pioneering research positions it well to capitalize on the potential of genome-editing therapies.

Caribou Biosciences faces several potential risks and challenges common to clinical-stage biopharmaceutical companies. These include uncertainties in clinical trials, regulatory approval processes, and market competition. However, Caribou's risk management strategies and scientific expertise serve as potential mitigating factors.

CRBU Stock Price History

CRBU Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
CRBU Oct 2024 5.000 put
Caribou Biosciences Shares Fall on Wall Street Miss
CRBU Oct 2024 2.500 call
CRBU Mar 2024 7.500 put
See More Headlines
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$34.48 million
Book Value
$4.17 per share


Free Float
Market Cap
$347.73 million
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

CRBU Stock Analysis - Frequently Asked Questions

Should I buy or sell Caribou Biosciences stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Caribou Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRBU shares.
View CRBU analyst ratings
or view top-rated stocks.

What is Caribou Biosciences' stock price target for 2024?

4 Wall Street analysts have issued twelve-month target prices for Caribou Biosciences' shares. Their CRBU share price targets range from $13.00 to $30.00. On average, they predict the company's stock price to reach $22.50 in the next year. This suggests a possible upside of 482.9% from the stock's current price.
View analysts price targets for CRBU
or view top-rated stocks among Wall Street analysts.

How have CRBU shares performed in 2024?

Caribou Biosciences' stock was trading at $5.73 at the beginning of the year. Since then, CRBU shares have decreased by 32.6% and is now trading at $3.86.
View the best growth stocks for 2024 here

When is Caribou Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRBU earnings forecast

How were Caribou Biosciences' earnings last quarter?

Caribou Biosciences, Inc. (NASDAQ:CRBU) released its quarterly earnings data on Monday, March, 11th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.17. The firm earned $3.56 million during the quarter, compared to analyst estimates of $5.17 million. Caribou Biosciences had a negative net margin of 296.05% and a negative trailing twelve-month return on equity of 31.06%.

What ETFs hold Caribou Biosciences' stock?
When did Caribou Biosciences IPO?

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at a price of $14.00-$16.00 per share.

Who are Caribou Biosciences' major shareholders?

Caribou Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Green Alpha Advisors LLC (0.09%), Allspring Global Investments Holdings LLC (0.05%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Barbara G Mcclung, Ryan Fischesser, Steven Kanner and Syed Ali-Aamir Rizvi.
View institutional ownership trends

How do I buy shares of Caribou Biosciences?

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRBU) was last updated on 4/24/2024 by Staff

From Our Partners